More than 44,000 people have filed formal legal objections under Article 21 of the UK GDPR demanding NHS England stop the Palantir-powered Federated Data Platform from processing their personal health data. The coordinated campaign, organized by 38 Degrees, forces the NHS to either demonstrate a "compelling reason" to continue or halt processing — a legal mechanism with real teeth, not a petition. The objections sit atop a broader backlash. Hundreds of thousands have signed petitions calling for cancellation of the £330m, seven-year Palantir contract. Two House of Commons select committees have urged Labour to exercise a break clause that becomes available in February 2027. Health Secretary Andy Burnham faces a decision within months on whether to back or axe the deal. The opposition draws from multiple sources of distrust. Campaigners cite Palantir's contracts with the Israeli military and its work supporting ICE deportation operations under the Trump administration. Amnesty International staged a protest outside Palantir's London headquarters featuring a van styled as a shot-up Palestinian ambulance. David Murray, a retired IBM systems engineer among the objectors, captured the tension precisely: he supports robust NHS data systems but not the company operating them. Palantir pushes back with performance numbers. The company claims trusts using the FDP have recorded 117,000 additional operations, a 14.3% reduction in discharge delays for long-stay patients, and a 5.6% improvement in 28-day cancer diagnosis timelines. Executive VP Louis Mosley has dismissed critics as suffering from "Palantir derangement syndrome." CEO Alex Karp, when confronted by a protester alleging the company "kills Palestinians," responded: "Mostly terrorists, that's true." The core structural question is not whether Palantir's software works but whether a national health data infrastructure should be operated by a US military-intelligence contractor with no accountability to British citizens. NHS England insists all organisations remain in control of their data within the FDP and that suppliers cannot access it for their own purposes. Palantir says patient data remains in the UK and is handled only according to NHS instructions. But the architecture tells a different story. The FDP is designed to connect sprawling health service datasets — surgery schedules, discharge planning, waiting lists — into a single integrated platform. Whoever builds and maintains that platform holds structural power over the system, regardless of formal data residency rules. The NHS's own chief executive, Jim Mackey, has acknowledged that the platform's benefits may not be as significant as claimed. The 44,000 objections are a legal forcing function. They require individual responses under data protection law, creating administrative burden and legal exposure. The objectors have also requested that processing halt while their claims are assessed. Whether or not the objections succeed legally, they have already succeeded politically — the question of Palantir's role in British healthcare is now a decision that must be made explicitly, not one that can drift through by default.
